Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The training initiative builds the foundations to explore further collaborations encompassing joint research efforts, leadership programmes, and a shared commitment to advancing clinical trials.

Prof Richard Hobbs with CNBG colleagues in China

The Nuffield Department of Primary Care Health Sciences (NDPCHS) is set to impart its expertise in clinical trials to China National Biotec Group (CNBG), the largest vaccine biotech in China and a pivotal part of Sinopharm, China's leading pharmaceutical company. 

The start of this partnership will see the renowned Clinical Trials Unit at NDPCHS deliver clinical trials training to CNBG. This marks the initiation of what is hoped will become a broader collaboration encompassing joint research efforts, leadership programmes, and a shared commitment to advancing clinical trials. 

Read the full story on the The Nuffield Department of Primary Care Health Sciences (NDPCHS)  website.

Similar stories

Terumo completes acquisition of University of Oxford spinout OrganOx for a record $1.5bn

OrganOx, a pioneering Oxford University spinout transforming kidney and liver transplantation, has been fully acquired by Terumo Corporation, a global medical technology company headquartered in Tokyo, Japan, for US$1.5 billion, marking the largest exit in Oxford University’s spinout portfolio to date and the first in excess of £1bn. The agreement for the acquisition was announced in August 2025.